Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosgonimeton Open-Label Extension in Alzheimer's Disease
NCT04886063Phase 3Terminated
- Sponsor
- LeonaBio
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of fosgonimeton in Alzheimer's disease (AD), sponsored by LeonaBio. Started Jun 2021; status: terminated.
02
Drugs
fosgonimeton
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04886063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886063.